
DEFINITIONS

In this prospectus, unless the context otherwise requires, the following terms shall have the meanings set out below. Certain other terms are explained in the section headed “Glossary of Technical Terms” in this prospectus.

“2017 Pre-IPO Investment”	the investment in our Company by the 2017 Pre-IPO Investors, the details are set out in the section headed “History, Development and Corporate Structure—Major Shareholding Changes of Our Group—2. 2017 Pre-IPO Investment” of this prospectus
“2017 Pre-IPO Investor(s)”	the investor(s) of the 2017 Pre-IPO Investment, namely Huajie, CICC Pucheng, CICC Kangrui, Huatai Ruihe and SDIC Chuanghe
“2019 Pre-IPO Investment”	the investment in our Company by the 2019 Pre-IPO Investors, the details are set out in the section headed “History, Development and Corporate Structure—Major Shareholding Changes of Our Group—4. 2019 Pre-IPO Investment” of this prospectus
“2020 Pre-IPO Investment”	the investment in our Company by the 2020 Pre-IPO Investors, the details are set out in the section headed “History, Development and Corporate Structure—Major Shareholding Changes of Our Group—5. 2020 Pre-IPO Investment” of this prospectus
“2020 Pre-IPO Investor(s)”	the investor(s) of the 2020 Pre-IPO Investment, namely CMP, AUT, LBC, CRF, Gamnat, Gortune, Happy Soul and CDG
“4C Medical”	4C Medical Technologies, Inc., a company incorporated under the laws of the State of Delaware and mainly engaged in the R&D of mitral and tricuspid valve devices in the United States
“Accountants’ Report”	the accountants’ report prepared by KPMG, details of which are set out in Appendix I to this prospectus
“Application Form(s)”	WHITE Application Form(s), YELLOW Application Form(s) and GREEN Application Form(s), or where the context so requires, any of them which is used in relation to the Hong Kong Public Offering and BLUE Application Form(s) in relation to the Preferential Offering
“Articles of Association” or “Articles” or “Memorandum of Association” or “Memorandum”	Memorandum and Articles of Association of our Company to be conditionally adopted on January 15, 2021 and to be effective on the Listing Date, a summary of which is set out

DEFINITIONS

	in “Appendix III—Summary of the Constitution of our Company and Cayman Islands Company Law” to this prospectus
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“Assured Entitlement”	the entitlement of the Qualifying MicroPort Shareholders to apply for the Reserved Shares on an assured basis pursuant to the Preferential Offering determined on the basis of their respective shareholdings in MicroPort on the Record Date
“AUT”	AUT-XVI Holdings Limited, an exempted company incorporated in the Cayman Islands and our Pre-IPO Investor
“Available Reserved Share(s)”	has the meaning ascribed to it in the section headed “Structure of the Global Offering—The Preferential Offering—Basis of Allocation for Applications for Reserved Shares” in this prospectus
“Beijing Chenxue”	Beijing Chenxue Enterprise Management Co., Ltd. (北京琛雪企業管理有限公司), a limited liability company established in the PRC on January 10, 2019 and a wholly-owned subsidiary of our Company
“Beneficial MicroPort Shareholder(s)”	any beneficial owner(s) of share of MicroPort whose shares of MicroPort are registered, as shown in the register of members of MicroPort, in the name of a registered shareholder of MicroPort on the Record Date
“BLUE Application Form(s)”	the application form(s) to be sent to Qualifying Microport Shareholders for the subscription of the Reserved Shares pursuant to the Preferential Offering
“Board”	the board of directors of our Company
“Business Day”	a day on which banks in Hong Kong are generally open for normal banking business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong
“BVI”	the British Virgin Islands
“CAGR”	compound annual growth rate
“CardioFlow BVI”	MicroPort CardioFlow Limited, a limited liability company incorporated in the BVI on January 17, 2019 and a wholly-owned subsidiary of our Company
“CardioFlow HK”	MicroPort CardioFlow International Corp. Limited (previously known as MicroPort CardioFlow China Corp.

DEFINITIONS

	Limited), a company incorporated in Hong Kong with limited liability on January 21, 2019 and a wholly-owned subsidiary of our Company
“Cayman Islands”	the Cayman Islands
“CCASS”	the Central Clearing and Settlement System established and operation by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct clearing participant or general clearing participant
“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant
“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant who may be an individual or joint individuals or a corporation
“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“CDG”	CDG Group Fund L.P., a limited partnership incorporated in the Cayman Islands and our Pre-IPO Investor
“CE Mark”	a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area
“Chengdu Xintuo”	Chengdu Xintuo Biotechnology Co., Ltd. (成都心拓生物科技有限公司), a limited liability company established in the PRC on June 8, 2020 and a wholly-owned subsidiary of our Company
“Chenxue Investment”	Shanghai Chenxue Enterprise Management Consulting Center (Limited Partnership) (上海琛雪企業管理諮詢中心(有限合夥)), previously known as Shanghai Chenxue Investment Management Center (Limited Partnership) (上海琛雪投資管理中心(有限合夥)), a limited partnership established in the PRC on November 2, 2015
“China,” “mainland China,” or “PRC”	People’s Republic of China, but for the purpose of this prospectus and for geographical reference only and except where the context requires otherwise, references in this prospectus do not apply to Hong Kong, Macau and Taiwan
“CICC Kangrui”	CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) (中金康瑞壹期(寧波)股權投資基金合夥企業(有限合夥)), a limited partnership established in the PRC and our Pre-IPO Investor

DEFINITIONS

“CICC Pucheng”	CICC Pucheng Investment Corporation Limited (中金浦成投資有限公司), a limited liability company incorporated in the PRC and our Pre-IPO Investor
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“CMP”	CMP Cardio Investment Limited, a limited liability company incorporated in the BVI and our Pre-IPO Investor
“CNIPA”	China National Intellectual Property Administration (國家知識產權局)
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Companies Act” or “Cayman Companies Act”	the Companies Act (As Revised) of the Cayman Islands, as amended, supplemented or otherwise modified from time to time
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Company” or “our Company”	MicroPort CardioFlow Medtech Corporation (微創心通醫療科技有限公司), a company with limited liability incorporated under the laws of the Cayman Islands on January 10, 2019
“connected person”	has the meaning ascribed thereto under the Listing Rules
“connected transaction”	has the meaning ascribed thereto under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed thereto under the Listing Rules and unless the context requires otherwise, refers to MicroPort and/or Shanghai MicroPort
“core connected person”	has the meaning ascribed thereto under the Listing Rules
“Core Product”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purposes of this prospectus, our Core Product refers to VitaFlow™ II
“CRF”	CRF Investment Holdings Company Limited, an exempted company incorporated in the Cayman Islands and our Pre-IPO Investor
“Director(s)” or “our Director(s)”	the director(s) of our Company, including all executive, non-executive and independent non-executive directors
“EEA”	the European Economic Area

DEFINITIONS

“EIT Law”	the PRC Enterprise Income Tax Law (中華人民共和國企業所得稅法), as enacted by the NPC on March 16, 2007 and effective on January 1, 2008, as amended, supplemented or otherwise modified from time to time
“EU”	the European Union
“EUIPO”	European Union Intellectual Property Office
“Extreme Conditions”	any extreme conditions or events, the occurrence of which will cause interruption to the ordinary course of business operations in Hong Kong and/or that may affect the Listing Date
“FDA”	U.S. Food and Drug Administration
“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., an independent market, research and consulting company
“Frost & Sullivan Report”	the report commissioned by our Company and independently prepared by Frost & Sullivan, a summary of which is set forth in the section headed “Industry Overview” in this prospectus
“Gamnat”	Gamnat Pte. Ltd., a limited liability company incorporated in Singapore and our Pre-IPO Investor
“GFA”	gross floor area
“Global Offering”	the Hong Kong Public Offering and the International Offering (including the Preferential Offering)
“Gortune”	Gortune Artemis Limited, a company incorporated in the BVI with limited liability and our Pre-IPO Investor
“GREEN Application Form(s)”	the application form(s) to be completed by the White Form eIPO Service Provider, Computershare Hong Kong Investor Services Limited
“Green Path for Innovative Medical Device”	the Special Procedures for Examination and Approval of Innovative Medical Devices (創新醫療器械特別審查程序) in China. For details, see “Regulatory Overview—Laws and Regulations Relating to Medical Devices—Special Procedures for Examination and approval of Innovative Medical Devices”
“Group”, “our Group”, “we”, “us”, or “our”	our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present

DEFINITIONS

	subsidiaries, the present subsidiaries of our Company and the businesses operated by such subsidiaries or their predecessors (as the case may be)
“Happy Soul”	Happy Soul Limited, a company incorporated in the BVI with limited liability and our Pre-IPO Investor
“HK\$” or “Hong Kong Dollars”	Hong Kong dollars, the lawful currency of Hong Kong
“HKFRSs”	Hong Kong Financial Reporting Standards
“HKSCC”	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“HKSCC Nominees”	HKSCC Nominees Limited, a wholly-owned subsidiary of HKSCC
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Offer Shares”	the 20,562,000 Shares initially offered by our Company for subscription at the Offer Price pursuant to the Hong Kong Public Offering (subject to reallocation as described in the section headed “Structure of the Global Offering” in this prospectus)
“Hong Kong Public Offering”	the offer for subscription of the Hong Kong Offer Shares to the public in Hong Kong (subject to reallocation as described in the section headed “Structure of the Global Offering”) at the Offer Price (plus brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005%) on the terms and conditions described in the section headed “Structure of the Global Offering” in this prospectus and the Application Forms
“Hong Kong Share Registrar”	Computershare Hong Kong Investor Services Limited
“Hong Kong Underwriters”	the underwriters of the Hong Kong Public Offering whose names are set out in the section headed “Underwriting—Hong Kong Underwriters” in this prospectus
“Hong Kong Underwriting Agreement”	the underwriting agreement dated January 23, 2021 relating to the Hong Kong Public Offering entered into by, among others, our Company, Microport, the Joint Sponsors, the Joint Global Coordinators and the Hong Kong Underwriters as further described in the section headed “Underwriting” in this prospectus
“Huajie”	Huajie (Tianjin) Medical Investment Partnership (Limited Partnership) (華杰(天津)醫療投資合夥企業(有限合夥)), a

DEFINITIONS

	limited partnership established in the PRC and our Pre-IPO Investor
“Huatai Ruihe”	Beijing Huatai Ruihe Healthcare Investment Fund llp (北京華泰瑞合醫療產業投資中心(有限合夥)), a limited partnership established in the PRC and our Pre-IPO Investor
“Independent Third Party(ies)”	party or parties that, to the best of our Directors’ knowledge, information and belief, having made all reasonable enquiries, is or are not a connected person of our Company within the meaning of the Listing Rules
“International Offer Shares”	the 185,058,000 Shares initially offered by our Company for subscription at the Offer Price pursuant to the International Offering (including, for the avoidance of doubt, 10,281,000 Reserved Shares for the Preferential Offering), together, where relevant, with any additional Shares which may be issued by our Company pursuant to the exercise of the Over-allotment Option, subject to reallocation as described in the section headed “Structure of the Global Offering” in this prospectus
“International Offering”	the offer of the International Offer Shares at the Offer Price to professional, institutional and other investors by the International Underwriters on behalf of our Company as further described in the section headed “Structure of the Global Offering” in this prospectus (for the avoidance of doubt, of the International Offer Shares initially being offered under the International Offering, the Reserved Shares are made available for subscription by the Qualifying MicroPort Shareholders under the Preferential Offering)
“International Underwriters”	the underwriters of the International Offering
“International Underwriting Agreement”	the underwriting agreement relating to the International Offering, which is expected to be entered into by, among others, our Company, MicroPort, the Joint Sponsors, the Joint Global Coordinators and the International Underwriters on or about the Price Determination Date
“Jipintang”	Jipintang Holding Co., Limited, a limited liability company incorporated in the BVI and our Pre-IPO Investor
“Joint Bookrunners” and “Joint Lead Managers”	J.P. Morgan Securities (Asia Pacific) Limited (<i>in relation to the Hong Kong Public Offering</i>), J.P. Morgan Securities plc (<i>in relation to the International Offering</i>), Citigroup Global Markets Asia Limited (<i>in relation to the Hong Kong Public Offering</i>), Citigroup Global Markets Limited (<i>in relation to</i>

DEFINITIONS

	<i>the International Offering</i>) and China International Capital Corporation Hong Kong Securities Limited
“Joint Global Coordinators”	J.P. Morgan Securities (Asia Pacific) Limited, Citigroup Global Markets Asia Limited and China International Capital Corporation Hong Kong Securities Limited
“Joint Sponsors”	J.P. Morgan Securities (Far East) Limited, Citigroup Global Markets Asia Limited and China International Capital Corporation Hong Kong Securities Limited
“Latest Practicable Date”	January 17, 2021, being the latest practicable date for the purpose of ascertaining certain information contained in this prospectus prior to its publication
“LBC”	LBC Sunshine Healthcare Fund L.P., an exempted limited partnership incorporated in the Cayman Islands and our Pre-IPO Investor
“Listing”	the listing of our Shares on the Main Board
“Listing Committee”	the listing committee of the Stock Exchange
“Listing Date”	the date, expected to be on or about February 4, 2021, on which the Shares are listed on the Stock Exchange and from which dealings in our Shares first commence on the Main Board
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the Growth Enterprise Market of the Stock Exchange
“MicroPort”	MicroPort Scientific Corporation (微創醫療科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 00853)
“MicroPort Group”	MicroPort and all of its subsidiaries
“MOFCOM” or “Ministry of Commerce”	the Ministry of Commerce of the PRC (中華人民共和國商務部)

DEFINITIONS

“MOH”	Ministry of Health (中華人民共和國衛生部), the predecessor of National Health and Family Planning Commission (中華人民共和國衛生和計劃生育委員會)
“MP CardioFlow”	Shanghai MicroPort CardioFlow Medtech Co., Ltd. (上海微創心通醫療科技有限公司), a limited liability company established in the PRC on May 21, 2015 and a wholly-owned subsidiary of our Company
“Nanhui Facility”	our manufacturing facility located in Nanhui District, Shanghai
“NMPA”	National Medical Products Administration (國家藥品監督管理局) and its predecessor the China Food and Drug Administration (國家食品藥品監督管理總局), including its sub-division, such as the Center for Medical Device Evaluation (國家藥品監督管理局醫療器械技術審評中心)
“Non-Qualifying MicroPort Shareholder(s)”	MicroPort Shareholder(s) whose name(s) appeared in the register of members of MicroPort on the Record Date and whose address(es) as shown in such register are in the Specified Territory or Beneficial MicroPort Shareholder(s) at that time who are otherwise known by MicroPort to be resident in the Specified Territory
“Offer Price”	the final offer price per Offer Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and the Stock Exchange trading fee of 0.005%) at which the Offer Shares are to be subscribed and to be determined in the manner further described in the section headed “Structure of the Global Offering” in this prospectus
“Offer Shares”	the Hong Kong Offer Shares and the International Offer Shares (including, for the avoidance of doubt, the Reserved Shares) together with, where relevant, any additional Shares which may be issued by our Company pursuant to the exercise of the Over-allotment Option
“Over-allotment Option”	the option expected to be granted by our Company to the International Underwriters, exercisable by the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) pursuant to the International Underwriting Agreement, pursuant to which our Company may be required to allot and issue up to an aggregate of 30,843,000 additional Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocation in the

DEFINITIONS

	International Offering, if any, further details of which are described in the section headed “Structure of the Global Offering” in this prospectus
“PBOC”	the People’s Bank of China (中國人民銀行)
“PRC Legal Advisers”	Commerce & Finance Law Offices
“Preferential Offering”	the preferential offering to the Qualifying MicroPort Shareholders of 10,281,000 Shares (representing approximately 5% of the Offer Shares initially being offered under the Global Offering) as an Assured Entitlement out of the International Offer Shares being offered under the International Offering at the Offer Price, on and subject to the terms and conditions set out in this prospectus and in the BLUE Application Form, as further described in the section headed “Structure of the Global Offering—The Preferential Offering” in this prospectus
“Preferred Shares”	the Series B Preferred Shares, the Series C Preferred Shares and the Series D Preferred Shares
“Pre-IPO Investment(s)”	the pre-IPO investment(s) in our Company, the details of which are set out in the section headed “History, Development and Corporate Structure—The Pre-IPO Investments”
“Pre-IPO Investor(s)”	the investor(s) of our Pre-IPO Investments
“Principal Share Registrar”	Tricor Services (Cayman Islands) Limited
“Price Determination Agreement”	the agreement to be entered into between our Company and the Joint Global Coordinators (for themselves and on behalf of the Underwriters) on the Price Determination Date to record and fix the Offer Price
“Price Determination Date”	the date, expected to be on or about January 29, 2021, on which the Offer Price will be determined, or such later time as the Joint Global Coordinators (for themselves and on behalf of the Underwriters) and our Company may agree, but in any event, not later than February 1, 2021
“Qianyi Investment”	Qianyi Investment I L.P., a limited partnership organized in the Cayman Islands and our Pre-IPO Investor
“Qualified Institutional Buyer” or “QIB”	a qualified institutional buyer within the meaning of Rule 144A

DEFINITIONS

“Qualifying MicroPort Shareholder(s)”	MicroPort Shareholder(s), whose name(s) appeared on the register of members of MicroPort on the Record Date, other than the Non-Qualifying MicroPort Shareholders
“R&D”	research and development
“Record Date”	January 19, 2021, being the record date for determining the Assured Entitlement of the Qualifying MicroPort Shareholders to the Reserved Shares
“Regulation S”	Regulation S under the U.S. Securities Act
“Renminbi” or “RMB”	the lawful currency of the PRC
“Reserved Share(s)”	the 10,281,000 Shares being offered by our Company pursuant to the Preferential Offering at the Offer Price to the Qualifying MicroPort Shareholders as the Assured Entitlement, which are to be allocated out of the International Offer Shares as described in the section headed “Structure of the Global Offering” in this prospectus
“Retained MicroPort Group”	MicroPort and its subsidiaries, excluding our Group
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	the State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
“SAIC”	the State Administration of Industry and Commerce of the PRC (中華人民共和國國家工商行政管理總局)
“SAMR”	the State Administration for Market Regulation (中華人民共和國國家市場監督管理總局), whose predecessor is the SAIC
“SAT”	the State Administration of Taxation of the PRC (中華人民共和國國家稅務總局)
“SDIC Chuanghe”	SDIC Chuanghe National Leading Fund of Emerging Industries VC (Limited Partnership) (國投創合國家新興產業創業投資引導基金(有限合夥)), a limited partnership established in the PRC and our Pre-IPO Investor
“Series B Preferred Shares”	the convertible series B preferred shares with a par value of US\$0.0001 per share in the authorized share capital of our Company allotted and issued to the Pre-IPO Investors during the Pre-IPO Investments, or the series B preferred shares with a par value of US\$0.000005 per share in the authorized share capital of the Company following the Share Subdivision

DEFINITIONS

“Series C Preferred Shares”	the convertible series C preferred shares with a par value of US\$0.0001 per share in the authorized share capital of our Company allotted and issued to the Pre-IPO Investors during the Pre-IPO Investments, or the series C preferred shares with a par value of US\$0.000005 per share in the authorized share capital of the Company following the Share Subdivision
“Series D Preferred Shares”	the convertible series D preferred shares with a par value of US\$0.0001 per share in the authorized share capital of our Company allotted and issued to the Pre-IPO Investors during the Pre-IPO Investments, or the series D preferred shares with a par value of US\$0.000005 per share in the authorized share capital of the Company following the Share Subdivision
“Series D Adjustment”	the issuance of 300,078 Series D Preferred Shares (before the Share Subdivision) to the 2020 Pre-IPO Investors, details of which are set out in “History, Development and Corporate Structure—Major Shareholding Changes of Our Group—5. 2020 Pre-IPO Investment”
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Shanghai Huahao”	Shanghai Huahao Enterprise Management Limited Partners (Limited Partnership) (上海鐮浩企業管理合夥企業(有限合夥)), a limited partnership established in the PRC and our Pre-IPO Investor
“Shanghai MicroPort”	Shanghai MicroPort Limited, a company incorporated in the BVI with limited liability on January 8, 2019, a wholly-owned subsidiary of MicroPort and one of our Controlling Shareholders
“Shanghai MicroPort Medical”	Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司), a limited liability company established in the PRC on May 15, 1998 and a wholly-owned subsidiary of MicroPort
“Share(s)”	ordinary share(s) in the share capital of our Company of US\$0.000005 each (as adjusted after the Share Subdivision)
“Shareholder(s)”	holder(s) of our Share(s)

DEFINITIONS

“Shareholders Agreement”	the first amended and restated shareholders agreement entered into among CardioFlow BVI, CardioFlow HK, MP CardioFlow, Shanghai MicroPort, CF Management Global Limited, Miracle Medical Limited, Stride and Strive Limited, Shanghai Huahao, CICC Kangrui, Huatai Ruihe, SDIC Chuanghe, Qianyi Investment, Haitong Fund, CMP, AUT, LBC, CRF, Gannat, Gortune, Happy Soul, CDG and our Company on April 29, 2020
“Share Option Scheme”	the share option scheme adopted by our Company on March 13, 2020, as amended from time to time, the principal terms of which are set out in “Appendix IV—Statutory and General Information—D. Share Option Scheme” to this prospectus
“Share Subdivision”	the subdivision of each share in the Company’s issued and unissued share capital with par value of US\$0.0001 each into twenty shares of the corresponding class with par value of US\$0.000005 each on January 15, 2021, the details of which are set out in “History, Development and Corporate Structure”
“Sophisticated Investor(s)”	has the meaning ascribed to it under Guidance Letter HKEX-GL92-18 issued by the Stock Exchange
“Specified Territory”	jurisdiction outside Hong Kong where, taking into account the legal restrictions under the applicable laws or requirements of the relevant regulatory body or stock exchange of such jurisdiction, MicroPort and our Company consider the exclusion of the MicroPort Shareholders with registered addresses in or who are otherwise known by MicroPort to be residents of, such jurisdiction from the Preferential Offering to be necessary or expedient
“Spin-off”	the separate listing of our Shares on the Main Board, which is expected to be effected by way of the Global Offering, including the Preferential Offering
“Stabilization Manager”	J.P. Morgan Securities (Asia Pacific) Limited
“State Council”	State Council of the PRC (中華人民共和國國務院)
“Stock Borrowing Agreement”	the stock borrowing agreement expected to be entered into between J.P. Morgan Securities Plc and Shanghai MicroPort on or around the Price Determination Date
“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited

DEFINITIONS

“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Takeovers Code”	the Codes on Takeovers and Mergers and Share Buy-backs issued by the SFC, as amended, supplemented or otherwise modified from time to time
“Track Record Period”	the two years ended December 31, 2018 and 2019 and the seven months ended July 31, 2020
“Underwriters”	the Hong Kong Underwriters and the International Underwriters
“Underwriting Agreements”	the Hong Kong Underwriting Agreement and the International Underwriting Agreement
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US dollar(s),” “US\$” or “USD”	United States dollars, the lawful currency of the United States
“U.S. persons”	U.S. persons as defined in Regulation S
“USPTO”	United States Patent and Trademark Office
“U.S. Securities Act”	the United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time, and the rules and regulations promulgated thereunder
“ValCare”	ValCare, Inc., a company incorporated under the laws of the State of Delaware and mainly engaged in the R&D of mitral valve and tricuspid valve medical devices
“VAT”	value-added tax; all amounts are exclusive of VAT in this prospectus except where indicated otherwise
“ WHITE Application Form(s)”	the applicable form(s) for use by the public who require(s) such Hong Kong Offer Shares to be issued in the applicant’s/ applicants’ own name(s)
“ WHITE Form eIPO”	the application process for Hong Kong Offer Shares with applications to be issued in the applicant’s own name by submitting applications online through the designated website of White Form eIPO at www.eipo.com.hk
“ WHITE Form eIPO Service Provider”	Computershare Hong Kong Investor Services Limited

DEFINITIONS

“ YELLOW Application Form(s)”	the application form(s) for use by the public who require(s) such Hong Kong Offer Shares to be deposited directly into CCASS
“Zhangjiang Facility”	our manufacturing facility located in Zhangjiang Hi-tech Park

For ease of reference, the names of the PRC laws and regulations, governmental authorities, institutions, natural persons or other entities (including certain of our subsidiaries) have been included in this prospectus in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail. English translations of official Chinese names are for identification purpose only.

For the purpose of this prospectus, references to “provinces” of China include provinces, municipalities under direct administration of the central government and provincial-level autonomous regions.